Drug Firm Glenmark Gets USFDA Nod For Generic Diabetes Drug To Market In US

Drug firm Glenmark said it has received approval from the US health regulator to market a generic medication to treat diabetes in the American market.

Topics

USFDA | Drug

Press Trust of India  |  New Delhi 



Glenmark Pharmaceuticals

Glenmark Pharmaceuticals

').insertAfter(".article-content__img");$(".article-content__img div").find('div').remove();

firm Glenmark said it has received approval from the US health regulator to market a generic medication to treat in the American market.

Glenmark Pharmaceuticals Inc, USA, a unit of the company, has received tentative approval from the US Food & Administration (US FDA) for Saxagliptin Tablets in strengths of 2.5 mg and 5 mg, the Mumbai-based maker said in a statement.

The company's product is the generic version of AstraZeneca AB's Onglyza tablets (2.5 mg and 5 mg), it added.

According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza tablets (2.5 mg and 5 mg) achieved annual sales of around USD 122.3 million.

Glenmark said its current portfolio consists of 179 products authorised for distribution in the US marketplace.

The drug firm has 46 abbreviated new drug applications (ANDAs) pending approval with the USFDA, it added.

In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio, it stated.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

First Published: Fri, February 17 2023. 12:55 IST


RECENT NEWS

JPMorgan's Berlin Moment: Chase Takes On Europe

There is something quietly symbolic about JPMorgan Chase choosing Berlin as its gateway into continental Europe. In a fo... Read more

What Strategy's Bitcoin Sale Really Tells Us

There is a moment in every bull run when the narrative starts to fray. Not with a crash, not with a scandal, but with so... Read more

Coutts Sets Scope On New Continent

Coutts steps into private marketsCoutts, the private bank best known for serving Britain’s wealthiest families and the... Read more

From Cypherpunk To Citadel

How Crypto Moved from the Wild West to the Mainstream Financial SystemA long-form analysis of Bitcoin's journey from fri... Read more

ACB Securities: Building Scale, Trust & Innovation

ACB Securities: Building Scale, Trust and Innovation in Vietnam’s Capital MarketsACB Securities (ACBS) is emerging as ... Read more

War Risk Returns To Markets As VIX Surges

For most of the past year, global markets behaved as though geopolitical risk had largely disappeared. Inflation was eas... Read more